Bonus BioGroup (XTAE:BONS) Net Margin %: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTAE:BONS Bonus BioGroup Ltd XTAE:BONS
22 GF Score
Price ₪0.27
! 3 Warning Signs
View Full Analysis

What is Bonus BioGroup Net Margin %?

Bonus BioGroup XTAE:BONS -0.38% 22 Net Margin % is 0.00% as of Dec. 2025. GuruFocus rates XTAE:BONS with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 943 Biotechnology companies, Bonus BioGroup ranks worse than 106044.43% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Bonus BioGroup's Net Income for the six months ended in Dec. 2025 was ₪-11.82 Mil. Bonus BioGroup's Revenue for the six months ended in Dec. 2025 was ₪0.00 Mil. Therefore, Bonus BioGroup's net margin for the quarter that ended in Dec. 2025 was 0.00%.

The historical rank and industry rank for Bonus BioGroup's Net Margin % or its related term are showing as below:


XTAE:BONS's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -89.56
* Ranked among companies with meaningful Net Margin % only.

Bonus BioGroup  (XTAE:BONS) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Bonus BioGroup Net Margin % Related Terms

Bonus BioGroup Net Margin % Historical Data

* Premium members only.

The historical data trend for Bonus BioGroup's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bonus BioGroup Net Margin % Chart

Bonus BioGroup Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Bonus BioGroup Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

XTAE:BONS vs VRTX, REGN, RVMD: Net Margin % Comparison

For the Biotechnology subindustry, Bonus BioGroup's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bonus BioGroup Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bonus BioGroup's Net Margin % distribution charts can be found below:

* The bar in red indicates where Bonus BioGroup's Net Margin % falls into.


XTAE:BONS
22GF Score
Bonus BioGroup Ltd XTAE:BONS
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bonus BioGroup Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Bonus BioGroup's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-24.49/0
= %

Bonus BioGroup's Net Margin for the quarter that ended in Dec. 2025 is calculated as

Net Margin=Net Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-11.822/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Bonus BioGroup (XTAE:BONS) has a Net Margin % of 0.00% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Bonus BioGroup and its competitors. According to the industry distribution chart, Bonus BioGroup ranks #999999 out of 943 companies in the Biotechnology industry.
Is Bonus BioGroup's Net Margin % too high?
Bonus BioGroup's current Net Margin % is 0.00%. Based on the distribution chart, Bonus BioGroup ranks #999999 out of 943 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Bonus BioGroup has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Bonus BioGroup's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bonus BioGroup ranks #999999 out of 943 companies for Net Margin %. This places Bonus BioGroup in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Bonus BioGroup and its competitors. Bonus BioGroup's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bonus BioGroup stock overvalued right now?
Bonus BioGroup (XTAE:BONS) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Bonus BioGroup's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Bonus BioGroup (XTAE:BONS), the current Net Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bonus BioGroup Business Description

Other Exchanges BBIXF:USA
Address Matam Advanced, Technology Park, P.O.B 15143, Haifa, ISR, 31905
Bonus BioGroup Ltd is an clinical-stage biotechnology company developing next-generation therapies for a variety of indications in the regenerative medicine field. Its products products, BonoFill and MesenCure.
22GF Score

Get the complete analysis for XTAE:BONS

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₪0.27
Price